接受极小和低致吐风险化疗患者的预防性止吐药物处方模式
该研究基于日本122家指定癌症诊疗医院的医保理赔数据库与医院癌症登记数据联动,分析了2010年9月1日至2012年12月31日期间接受极小或低致吐风险静脉化疗患者的预防性止吐药物处方情况。
要点
- 低致吐风险化疗中47.8%的给药处方了5-HT3受体拮抗剂联合地塞米松,极小致吐风险化疗中为2.8%。
- 低致吐风险组门诊化疗联合处方率53.1%(95%CI 51.6%-54.7%),高于住院患者的33.7%(95%CI 31.7%-35.9%)。
核心结论
- 相当数量接受极小和低致吐风险化疗的患者被处方了潜在不必要的预防性止吐药物,合理使用这些药物可减轻额外费用负担和潜在不良反应风险。
研究设计与样本
- 本研究为医保理赔数据库与医院癌症登记数据联动的二次分析,覆盖122家指定癌症诊疗医院,时间段为2010年9月1日至2012年12月31日。
- 纳入标准为诊断为乳腺癌、肺癌、结直肠癌、胃癌、宫颈癌或前列腺癌、诊断时年龄20岁及以上、接受极小或低致吐风险静脉化疗的患者,排除IV期患者。
- 共纳入8545例患者(5886例女性[68.9%],2659例男性[31.1%];平均[SD]年龄61.9[12.8]岁),共73577次化疗给药,其中极小致吐风险2464例患者、22619次给药,低致吐风险6081例患者、50958次给药。
- 数据分析时间为2014年3月20日至2016年6月30日。
主要发现
- 低致吐风险化疗中有24373次给药(47.8%)处方了5-HT3受体拮抗剂联合地塞米松,极小致吐风险化疗中有633次给药(2.8%)处方了上述联合方案。
- 低致吐风险组门诊化疗联合处方率为53.1%(95%CI 51.6%-54.7%),高于住院患者的33.7%(95%CI 31.7%-35.9%)。
关键数值与推荐
- 主要结局指标为处方预防性止吐药物(神经激肽1受体拮抗剂、5-HT3受体拮抗剂和/或地塞米松)的化疗给药百分比。
- 潜在不必要止吐药物费用采用2011年国民健康保险药品价格表估算。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The use of antiemetic drugs for patients receiving chemotherapy with low or minimal emetic risk has been recognized as a growing concern for health care costs and patients' welfare. Relatively few studies have examined antiemetic prophylaxis or treatment of emesis associated with chemotherapy with lower emetic risk. OBJECTIVE: To describe the pattern in Japan of overprescribing prophylactic antiemetic drugs to patients who have received intravenous chemotherapy with minimal or low emetic risk. DESIGN, SETTING, AND PARTICIPANTS: This secondary analysis of a health insurance claims database linked with the hospital-based cancer registry of 122 designated cancer care hospitals covered the period from September 1, 2010, to December 31, 2012. Data were included from patients who (1) were diagnosed with breast, lung, colorectal, stomach, cervical, or prostate cancer; (2) were 20 years or older at the time of the diagnosis; and (3) received intravenous chemotherapy with minimal or low emetic risk. The data from patients with advanced stage cancer (stage IV) were excluded. Data were analyzed from March 20, 2014, to June 30, 2016. MAIN OUTCOMES AND MEASURES: The percentage of chemotherapy administration involving patients prescribed prophylactic antiemetic drugs, namely, a neurokinin 1 receptor antagonist, serotonin receptor antagonist, and/or dexamethasone, was calculated. The costs of potentially unnecessary antiemetic drugs were estimated using the National Health Insurance drug price list for 2011. RESULTS: A total of 8545 patients (5886 women [68.9%] and 2659 men [31.1%]; mean [SD] age, 61.9 [12.8] years) undergoing 73 577 administrations of chemotherapy with minimal emetic risk (2464 patients; 22 619 administrations) or low emetic risk (6081 patients; 50 958 administrations) were identified. Of these, patients who received 24 373 administrations of chemotherapy with a low emetic risk (47.8%) and 633 administrations of chemotherapy with a minimal emetic risk (2.8%) were prescribed serotonin receptor antagonists and dexamethasone. Outpatients in the low emetic risk group underwent more frequent administration of chemotherapy that included prescription of both drugs (53.1% of the chemotherapy; 95% CI, 51.6%-54.7%) compared with inpatients (33.7% of the chemotherapy; 95% CI, 31.7%-35.9%). Consequently, approximately ¥170 million (US $1.6 million) was unnecessarily spent on prophylactic antiemetic drugs for these patients. CONCLUSIONS AND RELEVANCE: A substantial number of patients receiving chemotherapy with minimal and low emetic risk were prescribed potentially unnecessary prophylactic antiemetic drugs. The judicious use of these drugs could spare the burden of extra costs and the potential risk for adverse effects for patients.
引用
- Okuyama A, Nakamura F, Higashi T, et al. Prescription of Prophylactic Antiemetic Drugs for Patients Receiving Chemotherapy With Minimal and Low Emetic Risk. JAMA Oncol. 2017. PMID: 27812688. doi:10.1001/jamaoncol.2016.4096
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。